Format

Send to

Choose Destination
J Clin Psychiatry. 2012;73 Suppl 1:37-41. doi: 10.4088/JCP.11096su1c.06.

The use of monoamine oxidase inhibitors in primary care.

Author information

1
Department of Family Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts, USA. larry.culpepper@bmc.org

Abstract

Although primary care clinicians have developed considerable expertise in managing patients with major depressive disorder, and a range of treatment strategies is currently available, some patients still fail to reach remission. Two strategies have fallen out of common use: treating patients with monoamine oxidase inhibitors (MAOIs) and subgrouping patients by diagnosis when selecting antidepressant treatment. Monoamine oxidase inhibitors became less popular because other treatments were perceived to be safer and easier to use. However, a newer transdermal formulation of an MAOI that limits the need for the dietary restrictions of oral MAOIs may make it worthwhile to consider using this class of medication in patients who have failed several treatment trials. Although adverse events due to patients' diets are less likely with the transdermal MAOI, clinicians should still be alert for drug interactions and observe recommended washout periods. Patients who may benefit from MAOI treatment include those with treatment-resistant depression, atypical depression, anxiety, or anergic bipolar depression and those who have experienced intolerable metabolic or sexual side effects with other medications.

PMID:
22951241
DOI:
10.4088/JCP.11096su1c.06
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Physicians Postgraduate Press, Inc.
Loading ...
Support Center